Cubist Pharmaceuticals News
Cubist Reaches New 52-Week High (CBST)
6:15 AMCubist Pharmaceuticals (Nasdaq:CBST) hit a new 52-week high Monday as it is currently trading at $49.94, above its previous 52-week high of $49.86 with 49,619 shares traded as of 9:50 a.m. ET. Average volume has been 760,600 shares over the past 30 days.
Cubist Achieves Top Biotech Ranking in Globe 100 List
Business Wire May 19For the fifth consecutive year, Cubist Pharmaceuticals, Inc. has been named to the Globe 100 annual list, the Boston Globe’s annual ranking of the 100 top-performing public companies headquartered in Massachusetts.
Pipeline Progress at Gilead
May 16Pipeline Progress at Gilead - Analyst Blog
Zacks May 16Gilead presented encouraging data on idelalisib.
Cempra/Toyama Ink Deal
May 15Cubist (CBST) Said to Bid $1B for Optimer (OPTR) Before Sales Proceeds - Reuters
Street Insider May 15Cempra/Toyama Ink Deal - Analyst Blog
Zacks May 15Cempra entered into an exclusive license and development agreement with Toyama Chemical for an antibiotic candidate, solithromycin
Is AstraZeneca Gearing Up for a Shopping Spree?
Fool May 15With the company's pipeline in turmoil, AstraZeneca looks into the acquisition game.
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CBST | 51.25 | +1.74 | +3.51% | 3.342B |
New watchlist
